Abstracts tagged "giant cell arteritis"

Abstract Number: 2681 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Santos Castañeda ⁴, Vicente Aldasoro Caceres ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Elena Becerra-Fernández ¹⁴, Marcelino Revenga ¹⁵, Noelia Álvarez-Rivas ¹⁶, Carles Galisteo ¹⁷, Francisca Sivera ¹⁸, Alejandro Olivé-Marqués ¹⁹, María Álvarez del buergo ²⁰, Luisa Marena-Rojas ²¹, Carlos Fernández-López ²², Francisco Navarro ²³, E. Raya ²⁴, Eva Galindez-Agirregoikoa ²⁵, Beatriz Arca ²⁶, Roser Solans-Laqué ²⁷, Arantxa Conesa ²⁸, Cristina Hidalgo ²⁹, Carlos Vazquez ³⁰, Jose Andrés Román-Ivorra ³¹, Pau Lluch ³², Sara Manrique ³³, P. Vela ³⁴, Eugenio de Miguel ³⁵, Carmen Torres-Martín ³⁶, Juan Carlos Nieto ³⁷, Carmen Ordas-Calvo ³⁸, Eva salgado-Pérez ³⁹, Cristina Luna-Gómez ⁴⁰, F. Javier Toyos-Sáenz De Miera ⁴¹, Nagore Fernández-Llanio ⁴², Antonio García ⁴³, Elena Aurrecoechea ⁶, Norberto Ortego ⁴⁴, Francisco Ortiz-Sanjuán ³¹, Montserrat Corteguera ³⁶, Jose Luis Hernández ¹, Miguel Angel González-Gay ⁴⁵ and Ricardo Blanco ⁴⁶, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁷Hospital Parc Taulí, Barcelona, Catalonia, Spain, ¹⁸Hospital General Universitario de Elda, Elda, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ²⁰Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ²¹Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ²²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²³Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, ²⁴Hospital San Cecilio, Granada, Andalucia, Spain, ²⁵Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁶Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²⁸Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, ²⁹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³⁰Hospital Miguel Servet, Zaragoza, Aragon, Spain, ³¹Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ³²Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ³³Hospital Regional de Málaga, Málaga, Andalucia, Spain, ³⁴Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ³⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ³⁶Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁷Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, ³⁸Hospital Cabueñes, Gijón, Asturias, Spain, ³⁹Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ⁴⁰Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ⁴¹Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ⁴²Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ⁴³Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ⁴⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, Granada, Spain, ⁴⁵Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It showed to be effective to induce remission, prevent relapses and…
Abstract Number: 293 • 2019 ACR/ARP Annual Meeting
False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign
Elisa Fernández¹, Irene Monjo ², Gema Bonilla ³, Chamaida Plasencia ⁴, Maria-Eugenia Miranda-Carus ², Alejandro Balsa ⁴ and Eugenio de Miguel ⁵, ¹Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁴Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis…
Abstract Number: 2658 • 2019 ACR/ARP Annual Meeting
Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Alicia Rodriguez-Pla¹, Lili Zhou ², Erin Ashbeck ³ and C. Kent Kwoh ⁴, ¹University of Arizona/Banner Health Medical Center, Tucson, AZ, ²The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, Tucson, AZ, ³The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Giant cell arteritis (GCA) has traditionally been diagnosed by a combination of symptoms, clinical findings, laboratory results, and temporal artery biopsy. More recently, imaging…
Abstract Number: 2683 • 2019 ACR/ARP Annual Meeting
Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis
Pieter Nienhuis¹, Riemer Slart ² and Elisabeth Brouwer ³, ¹Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen, Groningen, Groningen, Netherlands, ²Dept. of Nuclear Medicine and Molecular Imaging - University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Assessing cranial artery inflammation plays an important role in the diagnosis of cranial giant cell arteritis (GCA). Although an established tool for assessing large…
Abstract Number: 762 • 2019 ACR/ARP Annual Meeting
Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study
Mayra Tobar Jaramillo¹, Victor Santos Andrade ², Marina Scolnik ³, Luciano Fernando Lo Giudice ⁴, John Jaramillo Gallego ⁵, Valeria Scaglioni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Fundacion Valle de lili, Colombia, Cali, Valle del Cauca, Colombia, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As many other rheumatologic diseases, pathogenesis of Polymyalgia Rheumatica (PMR) isnot well understood. Genetic factors seem to play a role. Some studies have suggested…
Abstract Number: 2659 • 2019 ACR/ARP Annual Meeting
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Matthias Papo¹, Laure Delaval ¹, Hubert de BOYSSON ², Jean-François Viallard ³, Aurélie Foucher ⁴, Sébastien Humbert ⁵, Pierre Duffau ⁶, Anne Contis ⁷, Christian Agard ⁸, Claude Bachmeyer ⁹, Bruno Gombert ¹⁰, Loic Guillevin ¹¹, Maxime Samson ¹² and Benjamin Terrier ¹¹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²University Hospital of Caen, Caen, France, ³CHU Bordeaux, Bordeaux, France, ⁴Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Universitaire de la Réunion Saint Pierre, Reunion Island, France., Saint-Pierre, France, ⁵Department of internal medicine, CHU Jean Minjoz, Besancon, France, Besancon, France, ⁶Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France., Bordeaux, Aquitaine, France, ⁷Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁸CHU Nantes, Nantes, France, ⁹Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France, Paris, France, ¹⁰Rheumatology Department, Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France., La Rochelle, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²CHU Dijon, Dijon, France
Background/Purpose: Giant-cell arteritis (GCA) is a large-vessel vasculitis affecting patients >50 years, whose origin remains widely unelucidated. Recent studies demonstrated that myeloid disease-related somatic mutations…
Abstract Number: 2684 • 2019 ACR/ARP Annual Meeting
Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement
DIANA PRIETO- PENA¹, Mónica Calderón-Goercke ², Javier Loricera ³, Javier Narváez ⁴, Elena Aurrecoechea ⁵, Ignacio Villa ⁶, Santos Castañeda ⁷, Catalina Gómez-Arango ⁸, Antonio Mera ⁹, Eva Perez Pampín ⁹, Vicente Aldasoro Caceres ¹⁰, N Alvarez Rivas ¹¹, N Fernandez Llanio ¹², María Álvarez del buergo ¹³, Luisa Marena-Rojas ¹⁴, Francisca Sivera ¹⁵, Eva Galindez-Agirregoikoa ¹⁶, Roser Solans-Laqué ¹⁷, Susana Romero-Yuste ¹⁸, Lara Sanchez-Bilbao ¹⁹, Iñigo Gonzalez-Mazon ¹, Isabel Martínez Rodríguez ²⁰, Ignacio Banzo ²⁰, Miguel Angel González-Gay ²¹ and Ricardo Blanco ¹⁹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁸Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ⁹Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹⁰Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ¹¹H. Lucus Augusti, Lugo, Spain, ¹²H. Arnau de Vilanova, Lerida, Spain, ¹³Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ¹⁵Hospital General Universitario de Elda, Elda, Spain, ¹⁶Hospital de Basurto, Bilbao, Pais Vasco, Spain, ¹⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ¹⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large vasculitis in elderly patients. According to previous studies, 50% of patients with GCA in whom…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 2660 • 2019 ACR/ARP Annual Meeting
Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling
Mats Junek¹, Angela Hu ², Karen Beattie ³, Kimberly Legault ³, Stephanie Garner ⁴, Ryan Rebello ³ and Nader A. Khalidi ³, ¹McMaster University, Oakville, ²University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, Canada
Background/Purpose: It has been historically difficult to develop effective diagnostic strategies and criteria in giant cell arteritis (GCA). While temporal artery biopsy was previously thought…
Abstract Number: 2685 • 2019 ACR/ARP Annual Meeting
Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers
Victor Yang ¹, Benjamin Sutu ², Christopher McMaster ³, Claire Owen ¹, Alexander Strathmore ⁴, Gene-Siew Ngian ², Shereen Oon ⁴, Jessica Leung ¹, Ian Wicks ⁵, Russell Buchanan ¹ and David Liew¹, ¹Austin Health, Heidelberg, Victoria, Australia, ²Melbourne Health, Parkville, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, ⁴Melbourne Health, Melbourne, Victoria, Australia, ⁵Melbourne Health, Parkville, Australia
Background/Purpose: Temporal artery biopsy (TAB) is widely recognised as the diagnostic gold standard for GCA, despite having a poor sensitivity due to the presence of…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 2661 • 2019 ACR/ARP Annual Meeting
A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. The historical gold standard for diagnosis is a…
Abstract Number: 2686 • 2019 ACR/ARP Annual Meeting
Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry
Shirish Dubey¹, Jonathan Pinnell ², Carl Tiivas ¹, Kaushik Chaudhuri ¹ and Purnima Mehta ¹, ¹University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²University Hospital North Staffordshire NHS Trust, Stoke, United Kingdom
Background/Purpose: University Hospital Coventry and Warwickshire NHS Trust (UHCW) established its one stop Fast Track Pathway (FTP) for Giant Cell Arteritis (GCA) in 2013. It…
Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
Abstract Number: 2662 • 2019 ACR/ARP Annual Meeting
Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. Diagnosis requires a combination of clinical manifestations including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].